结缔组织病：利妥昔单抗退市对系统性红斑狼疮的未来意味着什么？
Connective tissue diseases: What does the death of Riquent hold for the future of SLE?
作者信息
Merrill Joan T, Buyon Jill P
出版信息
Nat Rev Rheumatol. 2009 Jun;5(6):306-7. doi: 10.1038/nrrheum.2009.99.
PMID:19491911
Abstract
In clinical trials testing new treatments for systemic lupus erythematosus (SLE), the failure of the 15-year drug development program for riquent (abetimus sodium) is the latest in a string of disappointments for a disease that has seen no new drugs approved in over 50 years.
摘要
在针对系统性红斑狼疮（SLE）新疗法的临床试验中，长达15年的瑞喹（阿贝替莫钠）药物研发项目失败，这是该疾病一连串失望事件中的最新一例，该疾病已有50多年未获批新药。
Zotero 插件